tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Iovance Biotherapeutics price target raised to $1.50 from $1 at Goldman Sachs
PremiumThe FlyIovance Biotherapeutics price target raised to $1.50 from $1 at Goldman Sachs
3M ago
Iovance Biotherapeutics Reports Strong Q3 2025 Growth
Premium
Company Announcements
Iovance Biotherapeutics Reports Strong Q3 2025 Growth
3M ago
Iovance Biotherapeutics Reports Positive Earnings Amid Growth
Premium
Company Announcements
Iovance Biotherapeutics Reports Positive Earnings Amid Growth
3M ago
Iovance Biotherapeutics’ Lifileucel Therapy: Promising Developments and Market Potential Justify Buy Rating
PremiumRatingsIovance Biotherapeutics’ Lifileucel Therapy: Promising Developments and Market Potential Justify Buy Rating
3M ago
Iovance Biotherapeutics reports clinical data from Phase 2 IOV-LUN-202 trial
Premium
The Fly
Iovance Biotherapeutics reports clinical data from Phase 2 IOV-LUN-202 trial
3M ago
Iovance Biotherapeutics price target lowered to $9 from $20 at H.C. Wainwright
Premium
The Fly
Iovance Biotherapeutics price target lowered to $9 from $20 at H.C. Wainwright
4M ago
Home Depot reports Q2 results, SoftBank invests $2B in Intel: Morning Buzz
PremiumThe FlyHome Depot reports Q2 results, SoftBank invests $2B in Intel: Morning Buzz
6M ago
Iovance Biotherapeutics’ Canadian Approval of AMTAGVI: A Milestone in T Cell Therapy and Stock Growth Potential
Premium
Ratings
Iovance Biotherapeutics’ Canadian Approval of AMTAGVI: A Milestone in T Cell Therapy and Stock Growth Potential
6M ago
Iovance Amtagvi receives Health Canada approval for advanced melanoma
Premium
The Fly
Iovance Amtagvi receives Health Canada approval for advanced melanoma
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100